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Introduction: Sideroblastic cardiomyopathy secondary
to repeated blood transfusions is a feared complication
in thalassaemia. Control of myocardial iron is thus
becoming the cornerstone of thalassaemia
management. Recent evidence suggests a role for
L-type Ca2+ channels in mediating iron uptake by the
heart. Blocking the cellular iron uptake through these
channels may add to the benefit of therapy to standard
chelation in reducing myocardial iron. We aim to
determine the efficacy of amlodipine (a calcium
channel blocker) as an adjunct to standard aggressive
chelation in retarding myocardial iron deposition in
thalassaemics with or without cardiomyopathy.
Outcomes: The primary outcome is to compare the
efficacy of amlodipine+chelation (intervention) versus
standard chelation (control) in retarding myocardial
iron deposition. Secondary outcomes include the effect
of amlodipine therapy on systolic and diastolic
function, strain and strain rate and liver iron content.
Methods and analysis: This is a single-centre,
parallel-group, prospective randomised control trial.
Twenty patients will be randomised in a 1:1 allocation
ratio into the intervention and control arms. In addition
to conventional echocardiography, MRI T2* values for
assessment of cardiac and liver iron load will be
obtained at baseline and at 6 and 12 months. Cardiac
T2* will be reported as the geometric mean and per
cent coefficient of variation, and an increase in cardiac
T2* values from baseline will be used as an end point
to compare the efficacy of therapy. A p Value of <0.05
will be considered significant.
Study setting: Department of Pediatric and Child
Health, Aga Khan University Hospital, Karachi, Pakistan.
Ethics and dissemination: This study has been
approved by the Ethics Review Committee and Clinical
Trials Unit at The Aga Khan University with respect to
scientific content and compliance with applicable
research and human subjects regulations. Findings will
be reported through scientific publications and research
conferences and project summary papers for
participants.
Trial registration number: ClinicalTrials.Gov.
Registration no: NCT02065492.
INTRODUCTION
Thalassaemia, a hereditary anaemia of varying
severity, is one of the most common inherited
disorders in Pakistan.1 Approximately 9000
children with β thalassaemia are born every
year, although no thalassaemia registry is
Strengths and limitations of this study
▪ Amlodipine for Myocardial Iron in Thalassemia
(AMIT) is the second randomised control trial to
date aimed at assessing the role of amlodipine in
reducing moderate-to-severe myocardial iron
load secondary to repeated blood transfusions.
▪ Our study will also be the first to assess the
association of changes in cardiac T2* values
with important clinical parameters of cardiac
function such as echocardiographic estimates of
left ventricular ejection fraction (LVEF), systolic
and diastolic function as well as myocardial
strain and strain rate analysis, at 6 and
12 months following amlodipine therapy.
▪ Owing to budget restrictions, we will not be able
to achieve the calculated sample size. Our pilot
study has helped establish the T2* modality in
Pakistan and will also help us determine the
feasibility to perform a larger trial with the goal
of recruiting the calculated sample size.
▪ Similarly, we will not be looking at the responses
of amlodipine controlling for the type of iron
chelator or regimen used.
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available in Pakistan. The estimated carrier rate is 5–7%,
which amounts to 9.8 million carriers in the entire
population.2
Haemosiderosis due to transfusion treatments is a
major cause of death in patients with thalassaemia
major.3 Iron overload can lead to iron deposits in many
tissues, particularly in the heart. It has also been shown
to be associated with elevated oxidative stress in tissues.
Iron overload conditions can lead to increased iron
uptake into myocardial cells, resulting in myocardial
damage and failure.4–7 Catastrophic deterioration in
cardiac function resulting in death may occur rapidly
once clinically obvious heart failure is present.8
Therefore, heart disease is the most important complica-
tion and the major determinant of survival in patients
with thalassaemia, responsible for more than half of the
deaths in this population.9 10 It may take the form of car-
diomyopathy, pulmonary hypertension, heart failure,
arrhythmias, pericarditis and myocarditis.9–12
Currently, the mechanism of iron uptake into myocar-
dial cells is not clearly understood. Growing evidence sug-
gests that L-type Ca2+ channels (L-TCCs) are a possible
pathway for ferrous iron (Fe2+) uptake into myocardial
cells under iron overload conditions.13 Several ﬁndings
have been shown to support the role of L-TCC in myocar-
dial iron transport.14 15 A study in an iron loaded rat
heart showed that iron uptake was increased by the
L-TCC agonist Bay K 8644 and inhibited by the L-TCC
blocker nifedipine.14–16 Oudit et al16 demonstrated that
treatments with L-TCC blockers such as amlodipine and
verapamil could not only lead to the inhibition of the
L-TCC current in myocardial cells, but also reduced myo-
cardial iron accumulation, decreased oxidative stress and
improved survival in iron-loaded mice.
Since iron overload patients can develop cardiomyop-
athy and heart failure,11 17 18 which serves as the major
cause of death in these patients, it is important that the
use of drugs such as amlodipine be studied for the pre-
vention of myocardial iron deposition.
Current clinical practice
In thalassaemia major, the current practice to prevent
iron overload is to start chelation therapy after the ﬁrst
10–20 transfusions or when serum ferritin levels rise
above 1000 µg/L. The standard recommended method
of administration of chelation therapy is slow subcutane-
ous infusion over 8–12 h of 10% deferoxamine (desf-
eral) solution (DFO), using an infusion pump or oral
deferasirox (DFX) or oral deferiprone (DFP). The
standard dose of deferoxamine is 20–40 mg/kg for chil-
dren and up to 50–60 mg/kg for adults as an 8–12 h
subcutaneous infusion for a minimum of 3–5 nights a
week. Patients with high degrees of iron loading or
those at increased risk of cardiac complications require
adjustments in chelation therapy. The dose of oral defer-
asirox is 20–40 mg/kg/day. Recent studies suggest a pos-
sible synergistic effect of combination therapy of DFP
with DFO, especially in reducing the myocardial iron
load. This has led to multiple studies aimed at assessing
the effectiveness of DFO, DFP and DFX either as mono-
therapy or as part of combination therapy in patients with
transfusion-dependent thalassaemia. The multicentre,
prospective Evaluation of Patients’ Iron Chelation with
Exjade (EPIC) trial has demonstrated the effectiveness of
DFX as monotherapy in reducing mild-to-moderate and
severe myocardial iron load, as documented by improve-
ments in cardiac T2* values at 12 months,19 along with
persistence of these improvements from baseline even
after 24 and 36 months of deferasirox treatment when
evaluated in a substudy of these patients.20 21 Pepe et al22
demonstrated that the combined DFP+DFO regimen and
DFP in monotherapy were not signiﬁcantly different in
removing myocardial iron and improving heart function,
when followed up to 18 months. Similarly, in a
meta-analysis by Maggio et al,23 myocardial iron concen-
tration measured as T2* was found to be not statistically
signiﬁcantly different in the DFP+DFO versus the
DFO-treated groups. This is in contrast to ﬁndings by
Tanner et al,24 who have demonstrated signiﬁcant
improvements in the combined treatment group com-
pared with the deferoxamine group in myocardial T2* as
well as absolute LVEF. Thus, algorithms involving single
or combination chelation therapies have been developed
and are used in different centres. As documented by
Veríssimo et al,25 the Scientiﬁc Committee of Associacao
Brasileira de Thalassemia (ABRASTA) have proposed an
evidence-based iron chelation protocol for patients with
thalassaemia under regular transfusions, directed by the
myocardial T2* values obtained. Attached as online sup-
plementary appendix A, the protocol proves useful in
helping to initiate appropriate chelation therapy particu-
larly in the setting of severe myocardial iron overload.
With the growing evidence that suggests L-TCCs as a
possible pathway for ferrous ions (Fe2+) uptake into
myocardial cells,13 we hypothesise that the use of L-type
calcium channel blockers such as amlodipine will lead
to a reduction in this myocardial iron deposition.
Null hypothesis
There is no difference between the efﬁcacy of chelation
plus amlodipine therapy and chelation therapy alone in
retarding the rate of myocardial iron deposition in
patients with thalassaemia with iron overload and a con-
stant transfusion need.
Alternate hypothesis
Chelation plus amlodipine therapy is more efﬁcacious
than chelation therapy alone in retarding the rate of
myocardial iron deposition in patients with thalassaemia
with iron overload and a constant transfusion need.
Primary objective
The aim of our study is to determine if amlodipine, an
L-type speciﬁc calcium channel blocker, in addition to
the standard aggressive chelation therapy, can retard the
deposition of iron in the myocardium of patients with
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thalassaemia with signiﬁcant myocardial iron load with
or without cardiomyopathy.
Secondary objectives
To determine if there is a difference in LV size, systolic
and diastolic function in patients receiving amlodipine
plus chelation therapy when compared with patients
who receive only chelation therapy.
METHODS
Operational definitions
1. Myocardial iron load (see online supplementary
appendix B for study protocol):
A. T2*: The myocardial T2* values in the mid-
ventricular septum in the normal participants
using a multiechocardiography acquisition is
equal to are 33.3±7.8 ms.26 A shortening of myo-
cardial T2* to <20 ms (implying increased myo-
cardial iron) is associated with an increased
chance of decreased LV function.27
B. Severity index based on T2*:25
– Normal T2* >20 ms,
– Mild 15–20 ms,
– Moderate 10–15 ms,
– Severe <10 ms.
C. Truncation model: Short T2* values (4–10 ms)
lead to a rapid decay in signal intensity with the
signals of later echocardiography images buried
in the background noise and motion. Therefore,
in order to make the best-ﬁt curve to an monoex-
ponential curve, all data points less than 2 SNR
(signal-to-noise ratio) will be removed.
2. Liver Iron load: The values for T2* in normal partici-
pants for the liver with standard acquisition and
multiechocardiography acquisition will be taken as
26.6±4.7 ms and 26.7±4.2 ms, respectively.26
3. LV systolic dysfunction: LV systolic dysfunction will be
deﬁned as following:
– EF z-score >−2: normal
– ≤−2 and >−3: mild
– ≤−3 and >−4: moderate
– ≤−4: severe.
4. Diastolic dysfunction: Diastolic dysfunction is deﬁned
by echocardiograph through stages 1–4, using mitral
inﬂow, pulmonary venous ﬂow and Doppler tissue
imaging of mitral annular motion as described by
Khouri et al.28 Mitral inﬂow at peak Valsalva and
colour M mode propagation velocity will not be done.
5. Congenital or acquired heart disease: Signiﬁcant con-
genital defects will include cyanotic heart diseases, acya-
notic heart diseases (atrial septal defect, ventricular
septal defect, patent ductus arteriosus), with moderate-
to-severe left to right shunt (as determined by the treat-
ing paediatric cardiologist), and moderate-to-severe
valvular disease (mitral stenosis/mitral regurgitation,
aortic stenosis/aortic regurgitation, tricuspid regurgita-
tion/tricuspid stenosis, pulmonary stenosis/pulmonary
regurgitation) whether congenital or acquired (other
than thalassaemia).
6. Heart failure: Deﬁned as patients with known signs
and symptoms of heart failure, such as worsening dys-
pnoea at rest or during exercise or exercise intoler-
ance (NYHA functional II and above).
Study design
The use of amlodipine to treat hypertension has been
established clinically. The role of this medication in retard-
ing myocardial iron uptake in increased iron states has
been demonstrated in mice models. To date, only a single
study has been published to assess the role of amlodipine
as an iron uptake inhibitor.29 Our study will therefore be
the largest study to date, and is a hybrid phase 2 and 3
randomised controlled trial. Utilising a prospective
randomised controlled method, patients presenting to a
single-center will undergo parallel group, simple random-
isation with a 1:1 allocation.
Sample size calculation
To date, there is only a single human study that has
been reported, and therefore limited information is
available for sample size calculation.
With the information gathered from Fernandes et al,29
using PASS 11 software, using a one-sided two-sample t test,
we calculated that group sample sizes of 23 in each arm
(intervention and control) achieve 90% power to detect a
difference of −6.6 between the null hypothesis that both
group means are 21.7 and the alternative hypothesis that
the mean of group 2 is 28.3 with known group SDs of 7.2
and 8.0 and with a signiﬁcance level (α) of 0.05000.
However, the sample size for our current study is dic-
tated by the grant budget. Our sample will therefore be
20 study participants. Given the 1:1 allocation ratio, 10
participants each will be randomised into either one of
two groups; the control group (arm A) will comprise of
standard chelation therapy alone while the intervention
group (arm B) will receive amlodipine in addition to the
standard chelation. Our future work and grant applica-
tion will encompass larger studies to recruit more
patients divided into different subgroups of chelation.
Treatment arms
Arm A: Receiving chelation therapy alone
Arm B: Receiving chelation therapy plus amlodipine.
Study population
Paediatric patients with thalassaemia aged 6–20 years
managed in the outpatient haematology clinics at Aga
Khan University Hospital (AKUH) will be considered for
enrolment if they meet the inclusion criteria.
Eligibility criteria
The following inclusion/exclusion criteria will be used
for selection:
Inclusion criteria:
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▸ Paediatric patients aged ≥6 and ≤20 years managed
at AKUH for at least 1 year;
▸ ≥10 blood transfusions in a lifetime;
▸ Transfusion need ≥180 mL/kg/year;
▸ Serum ferritin ≥1000 µg/dL;
▸ Patient deemed capable of receiving chelation
therapy (by treating haematologist) either by subcuta-
neous infusion of deferoxamine (desferal; 3–5 days a
week) or oral deferasirox (daily) or deferiprone
(oral) or a combination of desferal and deferiprone;
▸ Patients who have been on a stable chelation regimen
≥6 months;
▸ Completed and signed informed consent/assent.
Exclusion criteria:
▸ Patients with known hypersensitivity to amlodipine.
▸ Patients with known sinoatrial nodal disease or aortic
stenosis.
▸ Patients with known severe myocardial dysfunction,
deﬁned as an LVEF of ≤4 SD for age even without
symptoms.
▸ Patients with known signs and symptoms of heart
failure.
▸ Patients with a T2* value of <4 ms on cardiac MRI.
▸ Patients with systolic blood pressure (SBP) ≤2 SD for
age (systemic hypotension) at the time of enrolment.
▸ Patients with previously diagnosed signiﬁcant con-
genital heart diseases or acquired heart diseases
other than thalassaemia (as deﬁned earlier).
▸ Patients with known contraindications to MRI (pace-
makers, cerebral aneurysm metal clips, etc).
▸ Patient with a known history of developing tetany
after use of a calcium channel blocker.
▸ Known pregnancy.
Patient recruitment and randomisation process
As shown in online supplementary appendix B, once eli-
gible, parents of the patients presenting to the haematol-
ogy outpatient clinics will be approached by the
principal investigator (PI)/co-investigator for administer-
ing informed consent and assent, respectively, and as
applicable on the day of admission. As per Good
Clinical Practice (GCP) guidelines (GCP 4.8.11), a copy
of the signed dated informed consent will be provided
to the patient and the patients’ legally acceptable
representative.
After obtaining informed consent, the patients will be
recruited in the trial. The patients will be randomly
assigned to either of the two intervention arms, amlodi-
pine (0.1 mg/kg/day or maximum of 2.5 mg/day) plus
chelation therapy or chelation therapy alone.
Amlodipine is administered as a single daily dose.
Recruited patients will receive treatment accordingly.
Randomisation will be computerised; allocation conceal-
ment will be exercised by sequential participant identiﬁ-
cation, and arms randomised using sealed opaque
envelopes.
As per established clinical guidelines in Pakistan, as
seen in online supplementary appendices C and D of
the protocol, owing to the unavailability of cardiac MRI
T2* technology, the chelation dosing and types used
have commonly been dictated by serum ferritin levels.
Having recently acquired the technology of cardiac
T2* MRI for this project, the modality and its clinical
use has been now introduced in Pakistan, and we are
now informally basing the chelation on the values of
T2* obtained, as per the guidelines suggested by
Veríssimo et al (see online supplementary appendix A)
until more updated local guidelines are available at our
institution. The chelation therapy is therefore left to the
discretion of the treating haematologist. Since it is a
single centre study and the patients are predominantly
managed by two haematologists, we have been able to
initiate the informal chelation protocol in our study
patients, thus introducing standardisation of care. This,
along with our current randomisation process, we hope,
will help equally distribute the effect of the chelation in
both the arms. On the basis of this reason, we have
decided not to randomise on the type of chelation
therapy.
Blinding
While the primary physician and the patients will be
aware of the allocated arm, the readers involved in T2*
assessment will be blinded to the allocated arm.
Similarly, outcome assessors and data analysts will also be
blinded to the allocation.
Additional measures to ensure data safety and moni-
toring along with validation will be made, the details of
which will be discussed later in this protocol.
Study drug: amlodipine
Amlodipine is a long-acting L-type calcium channel
blocker that needs to be taken only once a day without
any dietary restrictions. Numerous studies have shown
that it is better tolerated when compared with other
L-type calcium channel blockers like nifedipine.30 It is
also available at an easily affordable price that allows
maximum compliance and makes the drug highly suit-
able for our study. Based on the studies available to date,
amlodipine should be initiated in children at a dose of
0.05–0.1 mg/kg/day given once daily. Younger children
appear to require higher doses, often as much as
0.3–0.4 mg/kg/day. The adult dose is 2.5–5 mg/day.31
The symptomatic adverse reactions produced by amlo-
dipine are tolerable and, if they become severe, can be
treated symptomatically; these include abdominal pain,
gastrointestinal (GI) disturbance, blurred vision, head-
ache, ﬂushing, palpitations, dizziness, somnolence, hypo-
tension and cough. The severe adverse effects of
amlodipine, which may give rise to further complica-
tions, include peripheral oedema and sinus bradycardia.
The contraindications to amlodipine use are hypoten-
sion, aortic stenosis and sinoatrial node disease. The
paediatric cardiology and haematology team will deal
with adverse events (AEs) associated with amlodipine
and treatment cost will be covered by the grant budget.
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The frequency of serious AEs (SAEs) requiring interven-
tion frequency of SAEs requiring intervention is <1%.
On this basis, we anticipate at the most one patient who
may develop severe AEs requiring interventions like stop-
ping the medication or adding a diuretic.
As part of the protocol, regular monthly follow-ups of
all the study participants in our paediatric cardiology
clinics will help us to ensure adequate compliance to
the study drug. Moreover, the treating haematologist will




Deferoxamine may cause injection site reactions, sys-
temic reactions (eg, abdominal pain, arthralgia, nausea,
vomiting), cardiovascular reactions (eg, hypotension
with too rapid IV infusion, tachycardia, shock), hyper-
sensitivity reactions (eg, anaphylactic reaction with or
without shock, angio-oedema, generalised rash, urti-
caria), haematological reactions (eg, thrombocytopaenia
and leucopaenia), hepatic dysfunction, musculoskeletal
reactions (eg, muscle spasms, growth retardation and
bone changes including metaphyseal dysplasia are
common in doses ≥60 mg/kg, especially those who
begin iron chelation in the ﬁrst 3 years of life; reduced
risk if doses are kept to ≤40 mg/kg) and neurological
disturbances (eg, dizziness, peripheral sensory, motor, or
mixed neuropathy, paraesthesias, seizures; exacerbation
or precipitation of aluminium-related dialysis encephal-
opathy), and respiratory reactions (eg, acute respiratory
distress syndrome with dyspnoea, cyanosis and/or inter-
stitial inﬁltrates) (chelation therapy protocol as per
online supplementary appendix A or C and D).
Deferasirox
Deferasirox does not appear to present any increased
overall burden in adverse effects when compared with
placebo (chelation therapy protocol as per online
supplementary appendix A or C and D). When com-
pared with deferoxamine, there is an absence of injec-
tion site effects, but an increase in GI effects, which
occurs in about 15% of patients. Other common effects
include transient rises in serum creatinine, back pain
and rash.
The haematology team as per their standard clinical
practice will deal with adverse effects and the cost
incurred will also be borne by the patient.
Study procedures and monitoring
Eligible patients meeting the inclusion/exclusion cri-
teria will be recruited over a 4-month period (following
registration on clinicaltrials.gov). Each patient will be
randomised into either of two study arms: amlodipine
plus chelation or chelation alone. All patients will
undergo the following tests at baseline and at 6 and
12 month follow-up visits:
1. Myocardial iron content using cardiac MRI and T2*
imaging;27 32
2. Liver iron content using MRI and T2* imaging;27 32
3. Myocardial systolic function using standard measures
(EF) and diastolic function using conventional and
tissue Doppler imaging;
4. Myocardial function using speckled tracking derived
strain and strain rate analysis;
5. Serum ferritin levels.
The cost of the aforementioned investigations is bud-
geted through the grant except for the cost of the
serum ferritin levels which will be borne by the patient.
In addition, patients will receive standard care and have
follow-up appointments as dictated by the chelation
therapy. If found to be hypotensive (SBP <−2SD for age)
or experiencing bradycardia (<−2SD for age adjusted
heart rate), they will be evaluated by a paediatric cardi-
ologist and managed accordingly. Patients who are per-
sistently hypotensive and experiencing bradycardia will
be taken off the medication and receive chelation only.
These patients will be considered as part of the amlodi-
pine arm during analysis (intension to treat). Dropouts
or patients lost to follow-up during the ﬁrst 6 months of
being in the study will be replaced. Dropouts after com-
pletion of the 6-month evaluation will not be replaced.
The treating haematologist will determine chelation
therapy modiﬁcation based on myocardial iron content.
Adverse events—identification, reporting and clinical
management
Definitions
Adverse event: An ‘Adverse Event’ (AE) is “any untoward
occurrence (physical, psychological, social, or eco-
nomic) in a human subject participating in research.”
The event is undesirable and has an unintended
outcome, but is not necessarily unexpected. The event
may have been described in the informed consent as a
risk of the study. AEs include abnormal laboratory ﬁnd-
ings, a symptom or disease temporarily associated with
the use of an investigational agent, or the progression of
disease, whether or not related to the medicinal (investi-
gational) product (ICH GCP 1.2).
Serious adverse event: An ‘Serious Adverse Event’ (SAE)
is any untoward medical occurrence that at any dose:
▸ Results in death,
▸ Is life-threatening,
▸ Requires inpatient hospitalisation or prolongation of
existing hospitalisation,
▸ Results in persistent or signiﬁcant disability/incapacity,
▸ Is a congenital anomaly/birth defect (ICH GCP 1.50).
Identifying, recording and reporting SAEs:
1. Fatal
Any death occurring within the trial period or within
28 days after the last dose of the investigational product
except for any death that is unequivocally due to pro-
gression of disease.
2. Life-threatening
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The term ‘life-threatening’ in the deﬁnition of
‘serious’ refers to an event in which the patient was at
risk of death at the time of the event; it does not refer to
an event that hypothetically might have caused death if
it were more severe.
3. Hospitalisation
If the AE resulted in admission to a hospital overnight,
or necessitated prolongation of a stay in hospital. This
excludes hospital stays for elective surgery or planned
procedures.
4. Disabling or incapacitating
If the AE resulted in signiﬁcant or persistent change,
impairment, damage or disruption in the patient’s
ability to conduct normal life functions.
5. Congenital anomaly
If exposure by either parent to trial drug, before con-
ception, or by the mother during pregnancy, is asso-
ciated with the presence of developmental abnormalities
at birth (ICH E2A).
All clinical adverse experiences and symptoms will be
recorded by the clinical staff on ‘Adverse Event Report
Forms’. These forms will be ﬁlled at the following time
points:
1. At the 6-month study visit.
2. At the 12-month study visit.
3. At all visits to the Clinical Trials Unit (CTU) phar-
macy for dispensing amlodipine. These are not study
visits.
4. At all routine visits to the outpatient haematology
clinic. These are not study visits.
5. At all monthly cardiology clinic visits that are part of
the study.
The start date, severity, treatment or action taken, stop
date or determination of ongoing status, and assessment
of causality will be noted for each event. SAEs will be
documented when identiﬁed and relevant follow-up
information recorded when available.
Reporting AEs
All SAEs will be reported to the sponsor within ﬁve
working days of the SAE being identiﬁed even if the
event is considered to be not related to the investiga-
tional product. SAEs will be reported to the Institutional
Review Board (IRB)/Ethics Committee (EC) per Aga
Khan University’s Institutional policy. Copies of reports
of all SAEs will be kept at the study site. A summary of
AEs will be submitted to the sponsor and the IRB/ECs
at least annually and to other entities (eg, safety moni-
toring board) if applicable. The anonymity of the par-
ticipant shall be respected when forwarding all
information. The participant’s name will not appear on
any form or attachment.
Managing AEs
AEs that require symptomatic management only will be
treated by the participant’s primary haematologist. AEs
that require hospitalisation will also be managed by the
participant’s primary haematologist and the costs
incurred will be covered by the research fund.
Cardiovascular AEs that require outpatient or inpatient
management will be treated by the PI and his cardiology
team and all costs incurred will be covered by the
research fund.
Magnetic resonance and T2* imaging
Myocardial T2* MRI is the most sensitive and easily
reproducible index of myocardial iron deposition cur-
rently available.32 Myocardial iron deposition can be
reproducibly quantiﬁed using T2*. This is the most sig-
niﬁcant variable for predicting a requirement for tar-
geted treatment of myocardial iron overload and it
cannot be replaced by serum ferritin, liver iron or any
other measurement. A shortening of myocardial T2* to
<20 ms (implying increased myocardial iron) is asso-
ciated with an increased chance of decreased LV func-
tion.27 For example, patients with T2* values >20 ms
have a very low chance of decreased LVEF. T2* values of
10–20 ms indicate up to a 10% chance of decreased
LVEF; 8–10 ms indicates an 18% chance; 6 ms indicates
a 38% chance; and T2* values of just 4 ms indicate a
70% chance of decreased LVEF.33
The following index will be used to categorise myocar-
dial iron deposition severity based on T2* values:25
– Normal: T2* ≥20 ms;
– Mild: T2* 15–20 ms;
– Moderate: T2* 10–15 ms;
– Severe: T2* <10 ms.
Excellent T2* reproducibility between scanners pro-
duced by two different manufacturers supports the feasi-
bility of widespread implementation of the
technique.32 33 Thus, the inclusion of cardiac T2* assess-
ment, in concert with conventional long-term assess-
ments of tissue iron loading, is mandatory for the
comprehensive evaluation of iron loading.
Patients will be scanned using the single breath-hold
multiecho technique. The multiecho sequence para-
meters will be as follows: for the measurement of myo-
cardial T2*, a single short axis mid-ventricular will be
acquired at 10 echo times (1.99–20.26 ms, which will
increase in 2.03 ms increments) in a single breath-hold.
A gradient-echo sequence will be used with a ﬂip angle
of 20°, a matrix of 90–256 pixels, a ﬁeld of view of
40 cm, and a sampling bandwidth of 814 Hz per pixel.
The TR in between the 10 radio frequency pulses
applied to each cardiac cycle will be 22.17 ms. A homo-
geneous full-thickness region of interest (ROI) will be
chosen in the LV septum, encompassing both epicardial
and endocardial regions. The signal intensity of this
region will be measured for each image using QMass
V.7.6, MEDIS software, and will then be plotted against
the echo time to form an exponential decay curve. To
derive T2*, an exponential trend line will be ﬁtted with
an equation in the form y Ke–TE/T2* where K repre-
sents a constant, TE represents the echo time and
y represents the image signal intensity.
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Given the known risk of sideroblastic cardiomyopathy
in the hearts of patients with thalassaemia, we expect
our T2* values to reﬂect this myocardial iron load as
substantially shorter (4–10 ms) values. These values can
potentially lead to a rapid decay in signal intensity with
the signals of later echocardiography images buried in
the background noise and motion. Therefore, in order
to make the best-ﬁt curve, we will employ the truncation
method as described in the literature,34 which will
exclude all data points less than a particular SNR, gener-
ated according to the algorithm described by Bonny
et al.35 For all practical purposes, as utilised in the litera-
ture, we will therefore remove data points <2 SNR in our
study for short T2* values. Figure 1 demonstrates the
practical application of the truncation model to account
for background noise.
Carpenter et al36 also attempted to provide calibration in
humans for cardiovascular magnetic resonance relaxation
parameter R2* (reciprocal of clinically measured T2*)
against actual myocardial iron concentration. They
reported that myocardial R2* provides a robust curvilinear
relationship when calibrated against chemically assayed
values of cardiac iron in postmortem studies. They also
reported that R2* mid-ventricular septal ROI was highly
representative of mean global myocardial iron (ﬁgure 2).
Liver: The liver T2* value will be determined as follows: a
single transaxial 10 mm slice through the centre of the
liver will be scanned at a series of 14 different echo times
(0.94–17.58 ms, which will increase in 1.28 ms increments),
using a multiecho gradient-echo sequence with a ﬂip angle
of 20°, a matrix of 128–128 pixels, a ﬁeld of view of 40 cm
and a sampling bandwidth of 1502 Hz per pixel. Both even
and odd echoes will be used. The TR between two radio
frequency pulses will be 200 ms, with no cardiac gating. In
the liver, a large ROI will be chosen in a homogeneous
area of the liver parenchyma without blood vessels. Analysis
will then be performed as described for the heart
multiecho.
Echocardiography indices
A detailed paediatric echocardiography will be per-
formed to rule out any undiagnosed structural heart
disease. This will be performed in the paediatric cardi-
ology echocardiography unit, according to standard
protocol using Philips IE33 or GE 9 machine with a
5–12 MHz phased array transducer.
The following measurements will be observed:
A. LV volume and systolic function: LV volumes and EF will
be obtained from apical 4 chamber and short axis
views using the 5/6×area×length method.37 These
values will be compared to anthropometric based
z-scores.
B. Diastolic function: Mitral and tricuspid E and A waves,
mitral and tricuspid E/A ratios, mitral lateral and
septal E′ tricuspid E′ and E/E′ ratios.
Speckle tracking
Longitudinal speckle tracking imaging derived strain peak
(in %) will be obtained using the software ofﬂine package
(TomTec Imaging Systems, Inc, Unterschleissheim,
Germany) by tracing images obtained from the apical 4
chamber view (ﬁgure 3). Using the speckle-tracking algo-
rithm, the package tracks a total of 49 points (ie, speckles)
along the ventricular wall and interventricular septum
(IVS). The ventricle is then divided into six segments,
three along the free wall (basal, mid and apical free wall)
and three along the IVS (basal, mid and apical septum),
and the average of the speckles in the respective segments
is displayed as the peak longitudinal strain for that
segment. We will also calculate the mean peak longitudinal
strain for the right ventricular (RV) and LV lateral free
walls and IVS as an average of the three segmental values
(base, mid and apex). The package also reports a global
longitudinal strain peak for RV and LV. Since longitudinal
ﬁbres shorten during systole, longitudinal strain is
reported as a negative value. Higher negative values reﬂect
larger deformation.
Time to peak longitudinal strain (ms) will be calcu-
lated for three segments each on the LV free wall, IVS
and RV free wall. Values for the three segments will be
averaged to calculate the average time to peak strain for
each wall (ﬁgure 3). The intraventricular RV delay will
be calculated as the difference between RV free wall and
IVS times to peak strain, LV intraventricular delay will be
calculated as the difference between LV free wall and
IVS times to peak strain, and the interventricular
(between RV and LV) delay will be calculated as the
Figure 1 Adapted from Carpenter et al. This graph
shows signal intensity (arbitrary units) plotted against
echocardiography time (milliseconds) for the hearts shown on
top. Heart 1 (with normal iron levels) has a shallow decay
curve with a T2* value of >20 ms. Heart 2, owing to severe
iron loading, has a much more rapid decay with T2* <10 ms.
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Figure 2 Adapted from
Carpenter et al correlated T2*
values to myocardial iron content.
The regression (solid line) and
95% confidence bands (dotted
lines) are shown and derived from
analysis of the log-log data shown
in E. (A) R2* plotted versus
myocardial iron concentration
measured from each myocardial
region of interest (ROI).
(B) R2* versus myocardial iron
concentration excluding heart 4.
(C) Mean R2* plotted versus
mean iron concentration for each
heart. (D) Mean R2* versus mean
iron concentration excluding heart
4. (E) ln(R2*) plotted versus ln
((Fe)) for all ROIs, including heart
4, showing the best-fit linear
regression line. (F) Mean
midseptal R2* versus mean
whole-heart R2* plotted against
the line of identity showing that
the septal R2* value is highly
representative of the whole-
heart R2*.
Figure 3 Sample showing ventricular strain assessment using speckle tracking. LA, left atrium; LV, left ventricle; RA, right
atrium; RV, right ventricle.
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difference between RV free wall and LV free wall times
to peak strain.
Data collection: Data will be collected using abstraction
forms. Adverse effects will also be collected using the AE
form. These forms and data spreadsheets will be kept
under lock and key. The computer library will be pass-
word protected. Any serious adverse effects associated
with amlodipine and its use will be reported to the ERC
and granting agency by the CTU and PI. amlodipine to
the Ethics Review Committee (ERC) and granting
agency will be the responsibility of the CTU and PI.
These events will also be monitored by the Data Safety
and Monitoring Board (DSMB).
STATISTICAL ANALYSIS
Outcome variables
▸ Our primary outcome is T2* values, which we will
measure in milliseconds. A T2* recording will be taken
at the initial visit, at 6 months and at 12 months.
▸ Secondary outcomes will be looking at differences in
absolute LV size, EF, strain and strain rate, diastolic
function as mentioned earlier. We will also look at the
liver iron content and rate of deposition in the liver.
Data will be entered in SPSS V.19. Continuous para-
meters will be presented as the mean with SD. However,
since T2* is not normally distributed, we will report T2*
as the geometric mean (antilog of the mean of the log
data) and per cent coefﬁcient of variation (CV—equiva-
lent to the variance of the mean in log scale) following
log transformation of data.
Mann Whitney U or Wilcoxon sign-rank test will be
used for testing of continuous variables. Fisher exact or
χ2 test will be used for categorical variables. A p value of
<0.05 will be used as signiﬁcance.
T2* calculations will be performed by two independ-
ent observers on 10 studies to account for interobserver
variability. At least 10 out of all the 60 potential T2*
cardiac MRIs and calculations (baseline and two
follow-up visits included) will be sent to an international
centre for validation. Similarly, myocardial strain analysis
will also be performed by two observers on 10 studies to
determine interobserver variability. One of the observers
will recalculate the strain and strain rate on 10 studies
after a week of the original measurements to help deter-
mine intraobserver variability.
Following completion of imaging at 6 months, an
interim analysis will be performed.
To ensure proper conduct of the study along with the
safety of participants and the validity and integrity of the
data, all demographical and working details as well as
data and statistical analysis will be reviewed by an inde-
pendent DSMB. The DSMB will comprise of a statisti-
cian, a paediatric cardiologist and a haematologist and
will be responsible for protecting the credibility of the
trial by virtue of its independence from the staff involved
in the trial, and will help to ensure the validity of study
results by reviewing data on participant accrual and
conducting independent interim reviews. A research
steering committee comprising of a haematologist, a
paediatrician and a paediatric health researcher will be
created to ensure effective running of the study.
PUBLICATION AND PRESENTATION
Timeline and study status
One year from approval. Patient recruitment will begin
immediately after registration on clinicaltrials.gov and
will continue for 4 months. The detailed study will be
completed within 12 months of ﬁnal recruitment and
will be sent to a leading journal for publication.
We have currently completed the recruitment of patients
for our project in September 2014. All recruited patients
have undergone baseline imaging and pertinent labora-
tory testing and clinical examinations. The participants
have been assigned to their respective arms with some of
our earlier recruits near to completing the ﬁrst 6 months
of the study. As mentioned in the protocol, repeat imaging
and serum ferritin levels will be obtained at 6 months. We
anticipate our 6-month imaging to begin from December
2014 and to continue up to March 2015. On the basis of
this timeline, we hope to complete our exit 12-month
imaging from June 2015 to September 2015 and conclude
our study by September 2015. As mentioned earlier, all
our study patients will be reviewed in the clinics regularly
and managed as per clinical needs.
Dissemination of results
Findings of this study will be reported through scientiﬁc
publications and research conferences. Additionally, the
ﬁndings will also be disseminated to the participants
after project completion through a project summary and
conclusion document distributed in an exit meeting and
pertinent patient awareness sessions will be planned with
the participants after the conclusion of the project.
Additional information about our future work and study
plans as well as clinical implications and future manage-
ment regimens will also be discussed.
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